PubMed Health⌕ Search

Biomedical subjects

F Ebeling

Publications and source records attributed to F Ebeling.

32 records · Page 2Linked to original sources
PubMed1991

Post-transfusion hepatitis after open-heart surgery in Finland--a prospective study.

A countrywide prospective study on open-heart surgery patients was performed between 1987 and 1989 to determine the prevalence and nature of post-transfusion hepatitis in Finland. Altogether 685 coronary by-pass operation patients, who received on average 12.3 units of blood products, were postoperatively followed for 6 months. Ten blood samples were drawn from each patient. Hepatitis was diagnosed when the alanine aminotransferase values exceeded the upper normal value 2.5 times in one sample and twice in another, and non-viral causes could reasonably be excluded. Eleven hepatitis cases (1.6%) were recorded with a mean incubation period of 8.4 weeks; all represented the non-A, non-B type. The majority had mild symptoms or were asymptomatic but two became icteric. Six patients (55%) had abnormal alanine aminotransferase values for at least 6 months, which indicates possible chronicity. These 685 open-heart surgery patients received a total of 8,436 units of blood products; thus the rate of NANBH cases per 1000 units was as low as 1.3. This is less than recently reported in six other prospective studies.

Adult↗
PubMed1991

Post-transfusion hepatitis C in Finland.

Six of 11 (55%) non-A, non-B hepatitis (NANBH) patients seroconverted to hepatitis C virus antibody (anti-HCV) positivity 8-16 weeks after transfusions in a prospective post-transfusion hepatitis study on 685 open-heart surgery patients in Finland. Five of them had a seropositive donor, and two of the five non-converted NANBH patients had received an anti-HCV positive unit. Among 36 studied donors who were positive in the anti-HCV ELISA, reactivity of both the antigen bands in a recombinant immunoblot assay (RIBA) for anti-HCV was significantly associated with NANBH (P < 0.00005) in the recipient. In addition, infective anti-HCV positive donors had raised ALT values more often than seropositive donors which caused no seroconversion or infection in the recipients (P = 0.0001).

Adult↗
PubMed1991

Alanine aminotransferase, gamma-glutamyltransferase, antibodies to hepatitis B core antigen and antibodies to hepatitis C virus in blood donor screening. A prospective study in Finland.

Alanine aminotransferase (ALT), gamma-glutamyl-transferase and hepatitis B core antibodies were evaluated as donor markers in a prospective study of 685 open-heart surgery patients. Of these three surrogate markers, only an ALT level greater than or equal to 2 SD above the log mean had a significant association with recipient non-A, non-B hepatitis (NANBH, p = 0.02). Antibodies to the hepatitis C virus (anti-HCV) were detected by an enzyme immunoassay in 7 of the 136 units transfused to the 11 NANBH patients and 29 of 3,650 not associated with hepatitis (p less than 0.001). Calculated from this subgroup of donors, the anti-HCV test would have a 15.6% positive predictive value with 0.92% donor loss and thus is superior as a primary screening marker to all the three surrogate tests. The predictive value could be substantially increased by subsequent ALT testing or by the use of a recombinant immunoblot anti-HCV assay.

Alanine Transaminase↗
PubMed1991

Transmission of hepatitis C virus to sexual partners of seropositive patients with bleeding disorders: a rare event.

Sexual transmission of hepatitis C virus (HCV) was studied in 30 partners to anti-HCV positive multitransfused patients with a bleeding disorder. Anti-HCV ELISA C-100 was used as a screening test. Positive results were confirmed with the first generation RIBA test. Indeterminate samples were tested also with the second generation RIBA to verify the positivity. The time of sexual exposure added up was at least 95 years. 29 partners were anti-HCV seronegative. Only 1 partner was anti-HCV indeterminate. Thus sexual transmission of HCV was a rare event.

Adult↗
PubMed1991

Post-transfusion hepatitis.

Prospective international studies have shown the incidence of post-transfusion hepatitis in the 1980s to vary between 2% and 31%. Rare cases of hepatitis B continue to occur despite donor screening for the hepatitis B surface antigen, but most are of the non-A, non-B type. Non-A, non-B hepatitis is typically mild and often subclinical in the acute phase but has a tendency to become chronic in about half the affected subjects. The recently characterised hepatitis C virus has been shown to cause most, if not all, transfusion associated non-A, non-B hepatitis. Hepatitis C seropositivity seems to be associated with viraemia and infectivity among blood donors, and donor screening for these antibodies has now been instituted in many countries. New assays now being developed are improving the sensitivity and specificity of this screening, which is estimated to prevent most cases perhaps 70 to 80% of post-transfusion hepatitis.

Blood Donors↗
PubMed1990

Antibodies to hepatitic C virus and chronic liver disease among Finnish patients with haemophilia.

Antibodies to hepatitis C virus, hepatitis B serology and liver enzymes were examined in 137 Finnish haemophiliac patients to detect signs of chronic viral hepatitis and its possible aetiological associations. The prevalence of raised alanine aminotransferase values was 37%. These were significantly associated with hepatitis C seropositivity but not with hepatitis B antibodies, severity of haemophilia or the type of clotting factor used in replacement therapy. The prevalence of hepatitis C seropositivity was 50%; it was significantly associated with severe haemophilia and with the use of large pool concentrates. The hepatitis C virus seems to be the major cause of chronic liver disease transmitted by clotting factors also in Finland, despite a somewhat lower seroprevalence than described elsewhere so far.

Adolescent↗